US 20060193928A1

( 12) Patent Application Publication ( 10) Pub. N o. : US 2006/0193928 A1

( 19) United States
Soman et al. ( 4 3) Pub. D ate: Aug. 31, 2006
( 5 4 ) N OVEL HERBAL COMPOSITION S AN D
PROCESS FOR PREPARATION THEREOF
( 7 6) Inv entor s : G ir is h Sudh akar Soman, ( US) ;
Sh r ikr is h na G ov ind Ph adke, ( US) ;
Autumn Blum, G ulf por t, FL ( US)
Cor r es pondence Addr es s :
Ar nold S. Weintr aub
Th e Weintr aub G r oup, P. L. C.
Suite 24 0
32000 N or th w es ter n High w ay
Far minton Hills , MI 4 8334 ( US)
( 21) Appl. N o. : 11/35 2, 134
( 22) Filed: Feb. 10, 2006
( 30) For eign Application Pr ior ity D ata
Feb. 10, 2005 ( IN ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 2/MUM/2005
Publication Clas s i? cation
( 5 1) Int. Cl.
A61K 36/00 ( 2006. 01)
( 5 2) Us . or . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 24 /7 25
( 5 7 ) ABSTRACT
A pr oces s f or obtaining Var ious us ef ul ex tr acts f r om at leas t
one h er b includes th e s teps of ex tr acting lypoph ilic ingr e
dients th r ough a s uper cr itical CO2 ex tr action pr oces s to
obtain a ? r s t ex tr act; s ubj ecting th e r es idue th er eof to a
s econd s uper cr itical CO2 and alcoh ol s olv ent pr oces s to
obtain s ligh tly polar compounds Wh ich de? ne a s econd
ex tr act and, any r es idue af ter th e s econd ex tr action is
s ubj ected to Water ex tr action to obtain a s till f ur th er ex tr act.
Th e Var ious th r ee ex tr acts ar e mix ed togeth er in Var ious
combinations to de? ne f ur th er ex tr acts and Wh ich ar e
admix ed With potentiating th er apeutic poWder s to enh ance
th e potentiated th er apeutic poWder s . Th e th er apeutic poW
der s Wh en admix ed With one or mor e ex tr acts may be
encaps ulated in a Vegetar ian gelcap.
US 2006/0193928 A1
N OVEL HERBAL COMPOSITION S AN D PROCESS
FOR PREPARATION THEREOF
BACKG ROUN D OF THE IN VEN TION
Field of th e Inv ention
[ 0001] Th e pr es ent inv ention r elates to potentiating a
th er apeutic pow der of h er b/h er bs by adding bene? cial
ex tr activ es eith er indiv idually or in combination containing
all th e temper atur e s ens itiv e lypoph ylic activ e ingr edients
Wh ich ar e f r ee f r om tox ic s olv ent r es idues and s ligh tly polar
and Water s oluble ex tr activ es . Th e pr es ent inv ention f ur th er
r elates to nov el compos itions compr is ing th e potentiated
th er apeutic poWder of h er b/h er bs compr is ing bene? cial
ex tr activ es of h er b/h er bs and r aW poWder of h er b/h er bs
th er eby obv iate th e need of inactiv e car r ier . Th e pr es ent
inv ention f ur th er r elates to a pr oces s of ex tr acting bene? cial
ex tr activ es f r om th e s elected h er bs pr ef er ably compr is ing all
th e temper atur e s ens itiv e lypoph ylic activ e ingr edients
Wh ich ar e f r ee f r om tox ic s olv ent r es idues and s ligh tly polar
and Water s oluble ex tr activ es .
[ 0002] Th er e ar e s ev er al knoWn h er bs in India, Wh ich ar e
us ed tr aditionally in h er bal f or mulations . Th e pr es ent Way of
us ing s uch h er bs in v ar ious f or mulations can be br oadly
clas s i? ed as under
[ 0003] i) Us e of h er bs f r es h ly h ar v es ted to make decoc
tions or f r es h j uice and f or mulating th e s ame in v ar ious
combinations as de? ned in th e Ayur v edic tex ts .
[ 0004 ] ii) Us e of h er bs or par ts of h er bs af ter h ar v es ting/
dr ying under s h ed and poWder ing s uch h er bs or par ts of
h er bs and mix ing s uch h er bs togeth er in th e f or m of
poWder and us ing th e s ame f or th e h ealth car e appli
cations ( eith er as a pr ev entiv e, cur ativ e or s uppor tiv e to
h uman or animal h ealth as s upplementar y or th er apeu
tic) .
[ 0005 ] Th e adminis ter ing th e mix tur e of dr ied h er b
poWder s , in r eq uir ed dos ages f or getting th e f ull bene? t
of th e th er apeutic pr oper ties of th e h er bs is v er y dif f i
cult due to h igh daily dos age r eq uir ement. Hence,
s ev er al better meth od of making h er bal f or mulations
h av e tr ied to impr ov e th e dos age as des cr ibed beloW.
[ 0006] iii) Fir s t s uch impr ov ement is by making
Ex tr acts of s uch poWder s f r om concentr ates of s uch
h er bs made in Water and us ing all th e ex tr activ e of s uch
h er bs f or bene? cial applications in h er bal h ealth car e
and h er bal dietar y s upplements in v ar ious f or ms like
poWder s , caps ules , tablets etc. Her e, it h as been
obs er v ed in many s cienti? c ev aluations , th at in s pite of
impr ov ing th e dos age of Water s oluble or only
High ly Polar ingr edients , th e f or mulations did not
of f er r emar kable bene? t of th e eq uiv alent dos age of
h er bal poWder s or mix tur es of th e h er bal poWder s . Th e
pr obable r eas on is th e h er bs ar e cons is ting of s ev er al
High ly Polar ( Water s oluble) , Sligh tly polar
( s oluble in alcoh ol) and N on Polar ( lypoph ylic) con
s tituents , Wh ich act eith er indiv idually or collectiv ely in
a s yner gis tic manner . HoW and Wh y th is h appens is s till
lar gely unknoWn to th e s cienti? c community. So s elec
tiv e us e of Water Soluble or only Polar ingr edients
do not giv e th e compar able bene? ts of eq uiv alent
dos age of h er b poWder s r epor ted in th e ear lier ev alu
ations .
Aug. 31, 2006
[ 0007 ] iv ) Th es e s h or tcomings Wer e impr ov ed upon by
US. Pat. N o. 5 , 4 94 , 668. As des cr ibed th er ein, th e polar
s olv ents Wer e us ed initially f or ex tr action and th en
s ubj ected th e r es idue to ex tr action us ing s ev er al h ydr o
car bon or petr oleum s olv ents s uch as Hex ane, Meth a
nol, Peteth er , Acetone etc. Fur th er s uch ex tr activ es
made, us ing polar s olv ent ( Water ) and h ydr ocar bon
s olv ents ( petr oleum s olv ents , Wh ich ar e s ligh tly polar
and non polar in natur e) Wer e combined togeth er to
f or m th e bene? cial ex tr acts f or us ing th em togeth er
and mix ing s uch bene? cial ex tr acts f r om v ar ious
h er bs togeth er and mix ing it With iner t ph ar maceutical
car r ier s like D icalcium ph os ph ate ( D CP) to of f er in
conv enient dos age and f or m f or us e in v ar ious h ealth
car e applications in caps ules or tablet f or ms .
[ 0008] Th is meth od of making a combination of Polar
and N on Polar bene? cial ex tr activ es h as f olloWing
knoWn s h or tcomings .
[ 0009] a) D ue to s ubj ecting th e h er b( s ) or par t of h er b( s )
to Water ex tr action ( f or getting th e polar bene? cial
ex tr acts ) , th e h er b poWder is s ubj ected to h igh tem
per atur es . Th is des tr oys many h eat s ens itiv e elements
in th e pr oces s . In many cas es , th e compos ition of s ome
natur al molecules in th e h er bs ch anges dr amatically
due to h ydr olys is . For ex ample, Wh en Clov e bud is
s ubj ected to h eat, th e eugenol acetate is conv er ted in
eugenol or Wh en SandalWood poWder is s ubj ected to
h eat th e s antelyl acetate is conv er ted into s antalol
becaus e of h ydr olys is . Many s uch minor h eat s ens itiv e
ingr edients ar e eith er completely des tr oyed or ch ange
th e f or m th er eby r educing th e bene? cial th er apeutic
ef f ects of th e h er bs .
[ 0010] b) Anoth er maj or s h or tcoming is us e of h ydr o
car bon petr oleum s olv ents f or ex tr acting th e h er b poW
der s /r es idues of h er b poWder s af ter r emov ing th e polar
( Water s oluble) ex tr activ es f r om th e h er b. Th e ex tr acts
obtained us ing s uch s olv ents like meth anol, h ex ane,
petr oleum eth er , acetone, toluene etc. ar e f ound to
contain r es idues of s uch s olv ents . Th e r es idues of
s olv ent ev en at ppm lev els , adminis ter ed or ally to
animals /h umans ar e potential car cinogens or tox ins .
[ 0011] c) Th e ex tr action car r ied out us ing s uch s olv ents ,
als o h as one mor e s er ious s h or tcoming. Th e temper a
tur e at th e time of s epar ation of ex tr activ es f r om th e
s olv ents is alWays mor e th an th e ex tr action temper a
tur e. Th is means th at th e ex tr activ es ar e s ubj ected to
h igh er temper atur e at th e time of s epar ation. Th is
des tr oys many temper atur e s ens itiv e ingr edients
pr es ent in th e ex tr act. Th e s olv ents als o s ome times
r eact With th e cons tituents and ch ange th e f or m of
many ingr edients .
[ 0012] d) Th e idea of us ing s uch ex tr activ es togeth er
along With ph ar maceutical car r ier s like D CP ( D i Cal
cium Ph os ph ate) or Malto D ex tr in means adminis tr a
tion of non- th er apeutically bene? cial ingr edients to th e
obj ect ( animal/h uman) . Th is def eats th e pur pos e of
adminis ter ing th e max imum th er apeutically bene? cial
ingr edients to th e obj ect. D ue to th is ex ces s load on th e
body/s ys tem of th e obj ect of non bene? cial , non
abs or bable matter h av ing no ph ar macological/bio
ch emical activ ity, r es ults in loWer ing th e e? icacy of th e
f or mulations .
US 2006/0193928 A1
[ 0013] Th es e s h or tcomings ar e eliminated by s uper cr itical
? uid ex tr action meth od, Wh ich ar e r epor ted in WO007 2861,
US. Pat. N o. 6, 7 61, 913, US. Pat. N o. 6, 5 7 6, 27 4 , US. Pat.
N o. 6, 35 2, 7 28, US 2002127 10 and US 20020197 34 1, etc.
[ 0014 ] WO07 2861 des cr ibes meth ods of ex tr acting and
pur if ying bioactiv e s ubs tances f r om v ar ious plants and
h er bs , s uch as Kav a r oot, Byr s onima s pecies , Aes culus
callf or nica, Cr alaegus mex icana, Simmonds ia ch inens is ,
Pf a? ia s pecies , Aller nanlh er a r epens , Bur s er a s pecies ,
Tur ner a s pecies , Per ez ia s pecies , Heimia s alicif olia,
Ps idium s pecies , Enler lobium s pecies , Pz ych opelalum 01a
coides , Lir ios ma ov ala, and Ch aunoch ilon kappler i, us ing
s uper cr itical ? uid ex tr action and/or ? uor ocar bon s olv ent
ex tr act. Th es e ex tr acts ar e f ur th er us ed in f or mulation.
[ 0015 ] US. Pat. N o. 6, 7 61, 913 des cr ibes th e compos itions
and meth ods f or th e pr ev ention and tr eatment of pain,
in? ammation and gas tr ointes tinal ir r itation. Th e compos i
tions compr is e a pur i? ed, biologically activ e ex tr act of
celer y s eed, and may f ur th er be co- f or mulated With an
additional analges ic or anti- in? ammator y compound. Th e
biologically activ e ex tr act of celer y s eed is pr epar ed by
s uper cr itical ? uid ex tr action. An alcoh olic ex tr act of f r es h
celer y s eed is mix ed With a s uitable ads or bant, and th en
s ubj ected to s uper cr itical ? uid ex tr action. Optionally, th e
r es ulting pr oduct is f ur th er tr eated or f r actionated.
[ 0016] US. 2002127 10 and US 20020197 34 1 des cr ibe
ph ys iologically s yner gis tic mix tur es of pomegr anate
ex tr acts along With pomegr anate s eed oil and meth ods of us e
th er eof . Th e pomegr anate ex tr act Was pr epar ed by s uper
cr itical ? uid ex tr action.
[ 0017 ] Th er e is no pr ior ar t Wh ich r epor ts meth od of
potentiating th e th er apeutic h er b/h er bs poWder by us ing
bene? cial ex tr activ es pr epar ed by s uper cr itical ? uid ex tr ac
tion and f ur th er us e in h ealth car e f or mulation.
OBJECTIVE
[ 0018] Th e main obj ectiv e of th e pr es ent inv ention is to
pr ov ide a s us tainable, ecologically bene? cial meth od of
potentiating th e th er apeutic h er b/h er bs poWder and us ing
th em in h ealth car e f or mulations , With bene? cial ex tr activ es
eith er indiv idually or in combinations containing all th e
temper atur e s ens itiv e lypoph ylic activ e ingr edients Wh ich
ar e f r ee f r om tox ic s olv ent r es idues and s ligh tly polar and
Water s oluble ex tr activ es .
SUMMARY OF THE IN VEN TION
[ 0019] Accor ding to th e pr es ent inv ention, th er e is pr o
v ided a meth od f or potentiation of poWder of h er b/h er bs by
adding bene? cial ex tr activ es eith er indiv idually or in com
bination containing all th e temper atur e s ens itiv e lypoph ylic
activ e ingr edients Wh ich ar e f r ee f r om tox ic s olv ent r es idues
and s ligh tly polar ( alcoh ol s oluble) and polar Water s oluble
ex tr activ es and a meth od f or us ing th e potentiated th er apeu
tic poWder of h er b/h er bs , in h ealth car e applications .
[ 0020] A meth od of potentiating th e th er apeutic poWder of
h er b/h er bs by adding bene? cial ex tr activ es eith er indiv idu
ally or in combination compr is ing cleaning and s h ed dr ying
th e s elected r aW h er b( s ) f or a par ticular h ealth bene? t;
pulv er iZ ing it into poWder f or m; mix ing th e ex tr acts C and
W of th e h er b/h er bs in dif f er ent pr opor tion des cr ibed in th e
f olloWing ex amples to potentiate th e s elected r aW h er b/h er bs
Aug. 31, 2006
poWder made as des cr ibed abov e along With Aer ated s ilica
to make a h omogeneous h igh ly potentiated h er b poWder ( s )
mix tur e in a f r ee ? oWing h omogeneous poWder f or m; f or
mulating th e f r ee ? oWing h omogeneous potentiated h er b
poWder /combination of poWder s in tablets , caps ules ( G ela
tin) or caps ules ( Vegetar ian) , Wh ich is a conv enient f or m f or
us e in h ealth car e applications .
[ 0021] Th e pr es ent inv ention f ur th er r elates to nov el com
pos itions compr is ing th e potentiated th er apeutic poWder of
h er b/h er bs compr is ing bene? cial ex tr activ es eith er indiv idu
ally or in combinations .
[ 0022] Accor ding to th e pr es ent inv ention, th er e is pr o
v ided a pr oces s of ex tr acting bene? cial ex tr activ es f r om th e
s elected h er bs pr ef er ably compr is ing all th e temper atur e
s ens itiv e lypoph ylic activ e ingr edients Wh ich ar e f r ee f r om
tox ic s olv ent r es idues and s ligh tly polar and Water s oluble
ex tr activ es .
[ 0023] Accor ding to th e pr es ent inv ention, a pr oces s of
ex tr acting bene? cial ex tr activ es f r om th e s elected h er bs
pr ef er ably compr is ing all th e temper atur e s ens itiv e lypo
ph ylic activ e ingr edients compr is es cleaning th e h er b/h er bs
and poWder ing th e h er b/h er bs ; s ubj ecting th e h er b/h er bs to
s uper cr itical CO2 ex tr action to obtain th e ex tr act containing
all temper atur e s ens itiv e lypoph ilic ( non polar ) ingr edients
( Ex tr act A) s oluble in s uper cr itical CO2; s ubj ecting th e
r es idual h er b af ter th e s uper cr itical s uper cr itical CO2 ex tr ac
tion to ex tr action us ing s uper cr itical CO2 and eth yl alcoh ol
as a co- s olv ent and obtaining an ex tr act containing alcoh ol
s oluble ( s ligh tly polar ) bene? cial ingr edients ( Ex tr act B) ;
combining ex tr act A and B to get Ex tr act C; and s ubj ecting
th e r es idual h er b/h er bs obtained af ter getting ex tr act B to
Water ex tr action and obtaining th e ex tr act in poWder f or m
containing polar ingr edients ( Ex tr act W) .
D ETAILED D ESCRIPTION
[ 0024 ] Th e pr es ent inv ention dis clos es a meth od of mak
ing potentiated th er apeutic poWder of h er b/h er bs by adding
bene? cial ex tr activ es f r om th e s elected h er bs pr ef er ably
compr is ing all th e temper atur e s ens itiv e lypoph ylic activ e
ingr edients Wh ich ar e f r ee f r om tox ic s olv ent r es idues and
s ligh tly polar alcoh ol s oluble ex tr activ es and Water s oluble
ex tr activ es .
[ 0025 ] Th e pr es ent inv ention dis clos es a meth od f or
potentiating th e th er apeutic poWder of h er b/h er bs by adding
bene? cial ex tr activ es eith er indiv idually or in combination
containing all th e temper atur e s ens itiv e lypoph ylic activ e
ingr edients Wh ich ar e f r ee f r om tox ic s olv ent r es idues and
s ligh tly polar and Water s oluble ex tr activ es .
[ 0026] Th e pr es ent inv ention f ur th er dis clos es nov el com
pos itions compr is ing th e potentiated th er apeutic poWder of
h er b/h er bs compr is ing bene? cial ex tr activ es eith er indiv idu
ally or in combinations .
[ 0027 ] Th e pr es ent inv ention dis clos es a pr oces s of
ex tr acting bene? cial ex tr activ es f r om th e s elected h er bs
pr ef er ably compr is ing all th e temper atur e s ens itiv e lypo
ph ylic activ e ingr edients Wh ich ar e f r ee f r om tox ic s olv ent
r es idues and s ligh tly polar and Water s oluble ex tr activ es .
[ 0028] Th e ter m h er b us ed in th e pr es ent inv ention h er e
is intended to cov er one or mor e th an one h er b depending
upon th e ? nal h ealth car e application.
US 2006/0193928 A1
[ 0029] Accor ding to th e pr es ent inv ention, a pr oces s f or
pr epar ing nov el h er bal compos itions compr is es th e f olloW
ing s teps
[ 0030] l. A pr oces s of ex tr acting bene? cial ex tr activ es
f r om th e s elected h er b/h er bs compr is ing:
[ 0031] 1. Cleaning th e h er b/h er bs and poWder ing th e
h er b/ h er bs : Th e h er b or par t of h er b Was dr ied under th e
s h ed af ter r emov ing th e ex ter nal impur ities . Such dr ied
h er b Was poWder ed in par ticle s iZ e r anging betWeen
0. 001 to 4 mm. It Was ens ur ed th at th e poWder contains
mois tur e les s th an 12%. Such poWder ed h er b Was th en
s ubj ected to Super cr itical CO2 ex tr action.
[ 0032] 2. Subj ecting th e h er b/h er bs to s uper cr itical CO2
ex tr action at a pr es s ur e v ar ying betWeen 80 Bar ( 80
kg/cm2) and 300 Bar ( 300 kg/cm2) at a temper atur e
r anging betWeen 31 C. and 4 5 C. Th e CO2 Was pas s ed
th r ough th e h er b f or a per iod of 2- 3 h our s depending
upon th e s iZ e of th e ex tr actor s and th e q uantity of h er b
loaded into th e ex tr actor at a time. Th e q uantity of CO2
to be pumped th r ough th e h er b v ar ies betWeen 10 kg of
CO2/kg of h er b to 4 0 kg of COZ /kg of h er b depending
upon th e s olubility of lypoph ylic compounds pr es ent in
th e h er b. Th e CO2 car r ied th e ex tr activ es to th e s epa
r ator Wh er e th e pr es s ur e of CO2 Was r educed to pr es
s ur e v ar ying betWeen 4 0 Bar to 65 Bar and temper atur e
betWeen 10 C. to 30 C. as r eq uir ed to s epar ate th e
s olute ( ex tr act) and th e C02.
[ 0033] Th is meth od of ex tr action knoWn as Super cr iti
cal CO2 ex tr action is th e s af es t meth od of ex tr action f or
dr ied h er bs . Th e ex tr act th us obtained contains all th e
temper atur e s ens itiv e minor ingr edients pr es ent in th e
h er b and als o all th e oth er lypoph ylic s oluble com
pounds . Th is ex tr act obtained is Ex tr act A.
[ 0034 ] 3. Subj ecting th e r es idual h er b poWder s af ter
getting Ex tr act A to ex tr action us ing mix tur e of CO2
and eth yl alcoh ol in pr opor tion of 90 to 97 % Super
cr itical CO2 and 3 to 10% of eth yl alcoh ol. Th e ex tr ac
tion Was car r ied out at th e pr es s ur e r anging betWeen 80
Bar and 300 Bar and temper atur e r anging betWeen 31
C. to 4 5 C. Th e q uantity of s olv ent pumped ( CO2+
Eth anol) v ar ies betWeen 5 kg/kg of h er bs to 4 0 kg/kg of
h er bs . Th e s olute ( ex tr act) and eth anol Wer e s epar ated
f r om th e CO2 on r educing th e s olv ent pr es s ur e betWeen
4 0 Bar and 65 Bar and temper atur e betWeen 10 C. to
30 C. Th e eth yl alcoh ol laced With ex tr act Was col
lected f r om th e s epar ator . Th e mix tur e Was th en s ub
j ected to v acuum dis tillation f or s epar ating th e eth yl
alcoh ol completely f r om th e s olute ( ex tr act) , Wh ich Was
Ex tr act B.
[ 0035 ] 4 . Combining th e ex tr act A and ex tr act B to
obtain Ex tr act C. Th is combined ex tr act is als o ter med
as SCO2 ex tr act, in th e f olloWing ex amples .
[ 0036] 5 . Subj ecting th e h er b poWder r es idue r emainder
f r om abov e ex tr action to Water ex tr action to obtain th e
Water - s oluble ex tr activ es in a pas te f or m. Th e ex tr act
obtained Was dr ied in tr ay dr yer s /v acuum dr yer or in
s pr ay dr ier to obtain f r ee ? oWing poWder ex tr act. Th is
is Ex tr act W.
[ 0037 ] Th e abov e ex tr action meth od Was applied on s ev
er al h er bs and th e ex tr acts C ( Super cr itical CO2 ex tr acts
Aug. 31, 2006
combined With ex tr acts obtained by Super cr itical CO2 With
Eth yl alcoh ol as co- s olv ent) Was in liq uid/v is cous /pas te
f or m. Th e pos t s uper cr itical Water ex tr act ( Ex tr act W) Was
als o obtained f r om th e s ame h er bs . Th is Was in a poWder
f or m.
[ 0038] Accor ding to th e pr es ent inv ention, th e pr oces s of
ex tr action h as f olloWing impor tant bene? ts :
[ 0039] 1. Th e combined ex tr acts th us obtained contain
all th e temper atur e s ens itiv e minor ingr edients pr es ent
in th e h er b/h er bs , Wh ich can contr ibute to th e th er a
peutic bene? t of th e h er b/h er bs .
[ 004 0] 2. Th e ex tr acts do not contain any h ar mf ul
s olv ent r es idues /car cinogens /tox ins .
[ 004 1] 3. Th e ex tr acts ar e mor e Wh olis tic or total in
ter ms of bene? cial ingr edients .
[ 004 2] Th es e s olv ent f r ee ex tr acts Wer e combined togeth er
and us ed f or potentiation of h er bs Wh ich Was us ed in h ealth
car e applications .
[ 004 3] Wh ole h er b poWder s Wer e us ed in th er apeutic
applications giv ing uniq ue adv antage of s yner gis tic actions
of many knoWn/unknoWn ingr edients in th e h er b, Wh ich
may or may not be pr es ent in th e s electiv e ex tr acts
obtained f r om th e h er b. It is th er ef or e v er y much bene? cial
to us e potentiated h er bal poWder With s uch knoWn ben
e? cial ex tr activ es .
[ 004 4 ] It is an accepted f act th at many cr ops like Wh eat,
Rice, and Potatoes etc ar e s ucces s f ully modi? ed us ing
G enetic modi? cation ( G M) tech nology f or incr eas ing th e
amount of bene? cial nutr ients in th e pr oduce. Af ter s ev
er al year s of us e, th is appr oach , h oWev er , is being q ues
tioned as to Wh eth er th e G enetic modi? cation is s af e or
Wh eth er it Will h av e long- ter m h ar mf ul ef f ects .
[ 004 5 ] Accor ding to th e pr es ent inv ention, th e meth od
adopted f or potentiating th e h er bs inv olv es a ph ys ical pr o
ces s of ex tr action to get th e bene? cial ex tr activ es With a
v er y s imilar or ganoleptic pr o? le of th e h er bs With out h av ing
any h ar mf ul s olv ent r es idues , Wh ich av oids need of genetic
modi? cation and us e s uch ex tr activ es f or potentiation of r aW
h er b poWder s .
[ 004 6] A meth od f or potentiating th er apeutic poWder of
h er b/h er bs by adding bene? cial ex tr activ es eith er indiv idu
ally or in combination compr is ing s electing h er b/h er bs or
par t th er eof to be us ed f or its knoWn h ealth bene? t and
cleaning f r om ex tr aneous impur ities af ter dr ying th e s ame
under s h ed; poWder ing th e h er b; s iev ing th e poWder to get
th e r aW h er b poWder of ? nenes s betWeen 0. 01 to 1. 5 mm and
adding bene? cial ex tr activ es eith er indiv idually or in com
bination containing all th e temper atur e s ens itiv e lypoph ylic
activ e ingr edients Wh ich ar e f r ee f r om tox ic s olv ent r es idues
and s ligh tly polar and Water s oluble ex tr activ es to th e r aW
h er b poWder .
[ 004 7 ] D if f er ent s uch r aW h er b poWder s Wer e us ed f or
dif f er ent h ealth bene? ts as des cr ibed in th e ex amples 1 to 15 .
Th is r aW h er b poWder ( s ) Wer e potentiated as des cr ibed
beloW.
[ 004 8] Th e ex tr activ es ( Ex tr act C & Ex tr act W) obtained
f r om v ar ious h er bs Wer e mix ed togeth er and th en mix ed
With s peci? c h er b/h er bs poWder of ? nenes s r anging betWeen
US 2006/0193928 A1
0. 01 mm and 1. 5 mm pr epar ed as des cr ibed abov e, along
w ith aer ated s ilica to make a f r ee ? ow ing pow der .
[ 004 9] A combination of at leas t tw o ex tr activ es of h er bs
( w h ich ar e mos t bene? cial ex tr activ es or h er b in ter ms of
ph ar macological and bioch emical activ ities ) ar e mix ed w ith
at leas t one r aw h er b pow der f r om th e s elected h er bs f or
s peci? c bene? ts to potentiate th e th er apeutica pow der of
h er b.
[ 005 0] For mulating th e f r ee ? ow ing h omogeneous poten
tiated pow der of h er b/h er bs in tablets , caps ules ( gelatin) or
caps ules ( Vegetar ian) , w h ich is a conv enient f or m f or us e in
h ealth car e applications .
[ 005 1] Accor ding to th e pr es ent inv ention, th e compos i
tion compr is es a combination of at leas t tw o ex tr activ es of
h er bs ( w h ich ar e mos t bene? cial ex tr activ es or h er b in
ter ms of ph ar macological and bioch emical activ ities ) mix ed
w ith at leas t one r aw h er b pow der f r om th e s elected h er bs f or
s peci? c bene? ts .
[ 005 2] Th e main f eatur e of th e pr es ent inv ention is to
adminis ter potentiated h er b pow der h av ing know n bene? t
and bene? cial ex tr activ es of th e s uppor ting h er bs togeth er
to ach iev e better th er apeutic ef f ect.
[ 005 3] Anoth er impor tant f eatur e of th e pr es ent inv ention
is th e us e of r aw pow der of h er b/h er bs in th e compos itions
th er eby obv iating th e need of inactiv e car r ier .
[ 005 4 ] Th e r aw h er b pow der ( in w h ich ex tr acts w er e
mix ed togeth er ) w as us ed ins tead of us ing any iner t car r ier
like D CP or Malto D ex tr in in th e compos ition.
[ 005 5 ] Accor ding to th e pr es ent inv ention, th e lypoph ylic
non- polar ex tr activ es and s ligh tly polar alcoh ol s oluble
ex tr activ es w h ich ar e in liq uid or pas te f or m and polar
ex tr activ es , w h ich ar e in pow der f or m, w er e combined
togeth er and w er e conv er ted in to a unif or m matr ix .
[ 005 6] Accor ding to th e pr es ent inv ention, th e r aw h er b
pow der us ed to impr ov e th er apeutic activ ity of th e f or mu
lation, as it contain all th e ingr edients pr es ent in th e h er b,
s ome of w h ich may not be av ailable to th e body f r om th e
ex tr acts w h ich ar e likely to be contr ibuting to th e th er apeutic
bene? ts of th e h er bs .
[ 005 7 ] Accor ding to th e pr es ent inv ention, th e us e of s uch
potentiated h er b matr ix eliminates th e neces s ity of us ing
iner t car r ier s s uch as D CP/Malto D ex tr in, w h ich ar e us eles s
in ter ms of th er apeutic bene? ts . Our meth od w ill de? nitely
of f er a mor e bene? cial ef f ect of th e h er b pow der ( s ) .
[ 005 8] Accor ding to th e pr es ent inv ention, th e ex tr acts of
dif f er ent ph ys ical natur e, ( i. e. Ex tr act C in liq uid or pas te
f or m and Ex tr act W in f r ee ? ow ing pow der f or m) w er e
combined and obtained a f r ee ? ow ing mix tur e; Aer ated
s ilica w as us ed as a dr ying agent, w h ich als o is know n to
of f er cer tain h ealth bene? ts .
[ 005 9] Adv antages of th e pr es ent inv ention
[ 0060] l. Retention of h eat s ens itiv e elements in
ex tr acts , f or potentiating th e h er b( s ) pow der ( s ) .
[ 0061] 2. Elimination of h ar mf ul s olv ent r es idues f r om
th e ph ar macologically bene? cial ex tr activ es .
[ 0062] 3. Elimination of N on bene? cial iner t car r ier s
f r om th e f or mulations .
Aug. 31, 2006
[ 0063] 4 . Potentiation of h er b pow der s w ith out making
any G enetic modi? cation, s o completely ecof r iendly
w ay of potentiation of h er bs .
[ 0064 ] 5 . Aer ated Silica us ed f or combining th e ingr e
dients als o of f er s h ealth bene? ts making all th e ingr e
dients in th e f or mulation bene? cial f or h ealth car e
applications .
[ 0065 ] It w ill be r eadily appar ent to one s killed in th e ar t
th at v ar ying s ubs titutions and modi? cations may be made to
th e inv ention dis clos ed h er ein w ith out depar ting f r om th e
s cope and s pir it of th e inv ention. Th us , it s h ould be under
s tood th at alth ough th e pr es ent inv ention h as been s peci?
cally dis clos ed by pr ef er r ed embodiments and optional
f eatur es , modi? cation and v ar iation of th e concepts h er ein
dis clos ed may be r es or ted to by th os e s killed in th e ar t, and
th at s uch modi? cations and v ar iations ar e cons ider ed to be
f alling w ith in th e s cope of th e inv ention. Th is can be us ed
f or h ealth car e applications f or all animals as w ell as h uman.
[ 0066] Th e f ollow ing ex amples ar e f or th e pur pos e of
illus tr ation of th e inv ention only and ar e not intended in any
w ay to limit th e s cope of th e inv ention.
EXAMPLE 1
[ 0067 ] Compos ition containing potentiated pow der of
As h w gandh a ( Wilh ania s omnif er a) and Sh atav ar i ( As par a
gus r acemos us ) f or ener giZ ing and r eliev ing s tr es s .
[ 0068] As h w agandh a r oot pow der 25 to 100 mg and
Sh atav ar i r oot pow der 25 to 80 mg potentiated w ith As h
w agandh a r oot SCO2 ex tr act 5 to 25 mg ( Ex tr act C) and
As h w agandh a r oot pos t s uper cr itical h ydr o ex tr act 80 to 200
mg ( Ex tr act W) w ith Sh atav ar i r oot SCO2 ex tr act 1 to 10 mg
( Ex tr act C) , and Sh atav ar i r oot pos t- s uper cr itical h ydr o
ph ilic ex tr act 100 to 4 80 mg ( Ex tr act W) . In or der to make
th is mix tur e f r ee ? ow ing, aer ated s ilica 10 to 100 mg w as
th or ough ly mix ed togeth er . Th is mix tur e w as th en us ed to
make eith er tablets , Har d gelatin caps ules or Veggie caps ules
25 0 to 900 mgs each . Th is uniq ue mix tur e of know adop
togens h elps in enh ancing ener gy lev els w h ile h elping to
allev iate f atigue. It pr omotes ph ys ical and mental h ealth and
h elps to s uppor t th e body s immune def ens es and enh ances
longev ity and h elps building v itality w h en adminis ter ed
or ally in des ir ed dos ages .
EXAMPLE 2
[ 0069] Compos ition containing a mix tur e of potentiated
pow der s of Bas il Leaf ( Ocimum s anctum) & Tur mer ic
( Cur cuma longa) cooked r h iZ ome f or s uppor ting upper
r es pir ator y f unctions
[ 007 0] Bas il w h ole h er b pow der 5 5 to 190 mg and Tur
mer ic r h iZ ome pow der 20 to 180 mg potentiated w ith Bas il
leaf CO2 ex tr act 10 to 4 0 mg ( Ex tr act C) , Bas il leaf pos t
s uper cr itical ex tr act 7 0 to 180 mg ( Ex tr act W) , Tur mer ic
r h iZ ome SCO2 ex tr act 35 to 90 mg ( Ex tr act C) , N eem leaf
( Az adir ach la indica) SCO2 ex tr act 2 to 17 mgs ( Ex tr act C) ,
Long pepper ( Piper longum) f r uit SCO2 ex tr act 2 to 22 mg
( Ex tr act C) and Long pepper pos t s uper cr itical h ydr o ex tr act
33 to 100 mgs ( Ex tr act W) . In or der to make th is mix tur e
f r ee ? ow ing, Aer ated s ilica 10 to 100 mg w as th or ough ly
mix ed togeth er . Th is mix tur e w as th en us ed to make eith er
tablets , h ar d gelatin caps ules or Veggie caps ules 25 0 to 900
mg each . Th is mix tur e h elps to elev ate body def ens e agains t
US 2006/0193928 A1
inf ections , to pr omote immunity and r es pir ator y h ealth ,
giv es s ooth ing ef f ect to upper r es pir ator y tr act Wh en admin
is ter ed or ally in des ir ed dos ages .
EXAMPLE 3
[ 007 1] Compos ition containing potentiated poWder of
Tur mer ic ( Cur cuma langa) r h iZ ome as anti- in? ammator y
agent and blood pur i? er .
[ 007 2] Tur mer ic r h iZ ome poWder 15 0 to 600 mgs poten
tiated With Tur mer ic r h iZ ome SCO2 ex tr acts 4 0 to 110 mg
( Ex tr act C) . In or der to make th is mix tur e f r ee ? ow ing,
Aer ated s ilica 30 to 100 mg Was th or ough ly mix ed togeth er .
Th is mix tur e Was th en us ed to make eith er tablets , h ar d
gelatin caps ules or Veggie caps ules 25 0 to 820 mgs each
Th is mix tur e s uppor ts s kin, h ealth and lus ter , acts as blood
pur i? er , h elps to r educe in? ammation, s uppor ts car diov as
cular f unctions Wh en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 4
[ 007 3] Compos ition containing potentiated poWder of
? nos por a car dif olia as immuno modulator & h epato pr o
tectiv e agent.
[ 007 4 ] ? nos por a car dif olia s tem poWder 100 to 4 00 mg
potentiated With ? nos por a car dif olia r oot SCO2 ex tr act 25
to 80 mg ( Ex tr act C) , ? nos por a car dif olia pos t s uper cr itical
h ydr o ex tr act 90 to 330 mg ( Ex tr act W) . In or der to make
th is mix tur e f r ee ? oWing, Aer ated s ilica 10 to 100 mg Was
th or ough ly mix ed togeth er . Th is mix tur e Was th en us ed to
make eith er tablets , h ar d gelatin caps ules or Veggie caps ules
25 0 to 900 mg each . Th is mix tur e h elps to r egulate liv er
f unctions , impr ov es immune s ys tem and body r es is tance
agains t inf ections , pr omotes longev ity Wh en adminis ter ed
or ally in des ir ed dos ages .
EXAMPLE 5
[ 007 5 ] Compos ition containing a mix tur e of Potentiated
Br ah mi ( Bacopa monnier i) poWder f or impar ting calm s leep
and h elping neur o f unctions .
[ 007 6] Br ah mi Wh ole h er b poWder 100 to 280 mg poten
tiated With Br ah mi leav es SCO2 ex tr act 10 to 4 5 mg ( Ex tr act
C) , Br ah mi leav es pos t s uper cr itical h ydr oph ilic ex tr act 115
to 4 5 0 mg of ( Ex tr act W) , Spikenar d ( N ar dos lach ys j ala
mans i) SCO2 ex tr act 2 to 30 mg ( Ex tr act C) . In or der to
make th is mix tur e f r ee ? oWing, Aer ated s ilica 20 to 100 mg
is th or ough ly mix ed togeth er . Th is mix tur e is th en us ed to
make eith er tablets , h ar d gelatin caps ules or Veggie caps ules
25 0 to 900 mg each . Th is uniq ue mix tur e h elps to r educe
s tr es s and anx iety, h elps impr ov e memor y and f ocus , h elps
impar ting r es tf ul calm s leep, and h elps impr ov e intelligence
and oth er br ain f unctions Wh en adminis ter ed or ally in
des ir ed dos ages .
EXAMPLE 6
[ 007 7 ] Compos ition containing a mix tur e of potentiated
Pomegr anate ( Punica gr analum) s eed and Licor ice ( G lycyr
r h iz a glabr a) poWder f or h elping f emale patients s uf f er ing
f r om Per i Menopaus al s yndr omes .
[ 007 8] Pomegr anate s eed poWder 20 to 100 mg and Lico
r ice poWder 60 to 100 mg potentiated With Pomegr anate
s eed SCO2 ex tr act 20 to 65 mg ( Ex tr act C) , Pomegr anate
pos t s uper cr itical h ydr o ex tr act 30 to 260 mg ( Ex tr act W) ,
Aug. 31, 2006
Licor ice r oot SCO2 ex tr act 4 to 20 mg ( Ex tr act C) , Licor ice
r oot pos t s uper cr itical h ydr oph ilic ex tr act 30 to 15 0 mg
( Ex tr act W) , As h Wagandh a r oot ( Wilh ania s omnif er a) SCO2
ex tr act 3 to 28 mg ( Ex tr act C) , As h Wagandh a r oot pos t
s uper cr itical h ydr oph ilic ex tr act 7 0 to 17 0 mg ( Ex tr act W) ,
T r ibulus Z er es lr is r oot SCO2 ex tr act 20 to 60 mg ( Ex tr act C)
and T r ibulus Z er es lr is r oot pos t s uper cr itical h ydr o ex tr act 30
to 90 mg ( Ex tr act W) . In or der to make th is mix tur e f r ee
? oWing, Aer ated s ilica 20 to 100 mg Was th or ough ly mix ed
togeth er . Th is mix tur e Was th en us ed to make eith er tablets ,
h ar d gelatin caps ules or Veggie caps ules 25 0 to 900 mg each .
Th is uniq ue mix tur e h elps to minimiZ e dis comf or t as s oci
ated With PMS, h elps to impr ov e h or monal imbalance, h elps
to incr eas e ener gy and v itality Wh en adminis ter ed or ally in
des ir ed dos ages .
EXAMPLE 7
[ 007 9] Compos ition containing potentiated Eclipla alba
poWder f or migr aine.
[ 0080] Eclipla alba pow der 15 to 7 0 mg and Emblica
poWder 20 to 80 mg potentiated With Eclipla alba r oot SCO2
ex tr act 7 to 33 mg ( Ex tr act C) , Eclipla alba r oot pos t
s uper cr itical h ydr oph ilic ex tr act 100 to 280 mg ( Ex tr act W) ,
G inger ( Z ingiber a? icz ' nale) r h iZ omes SCO2 ex tr act 3 to 22
mg ( Ex tr act C) , Emblica SCO2 ex tr act 5 to 28 mg ( Ex tr act
C) and Emblica h ydr oph ilic ex tr act 7 0 to 4 00 mg ( Ex tr act
W) . In or der to make th is mix tur e f r ee ? oWing, Aer ated
s ilica 20 to 100 mg Was th or ough ly mix ed togeth er . Th is
mix tur e Was th en us ed to make eith er tablets , h ar d gelatin
caps ules or Veggie caps ules 25 0 to 900 mg each . Th is
mix tur e of h er b complex h elps to s uppor t ps ych os omatic
f unctions , s uppor t gas tr ic and liv er f unctions , r educe ph ys i
cal and mental s tr es s , and neutr aliZ e th e tox ins accumulated
in th e body, th er eby h elping th e patients s uf f er ing f r om
migr aine Wh en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 8
[ 0081] Compos ition containing potentiated Fenugr eek
( Tr igonellaf aenum- gr aecum) poWder f or cur ing & s uppor t
ing car diov as cular conditions .
[ 0082] D ef atted Fenugr eek s eed poWder 210 to 5 00 mg
potentiated With Commiph ar a mukul SCO2 ex tr act 25 to 100
mg ( Ex tr act C) , Tur mer ic r h iZ ome ( Cur cuma langa) SCO2
ex tr act 4 0 to 120 mgs ( Ex tr act C) , ? nos por a car dif olia r oot
SCO2 ex tr act 5 to 35 mg ( Ex tr act C) and ? nos por a car di
f olia pos t- s uper cr itical h ydr oph ilic ex tr act 65 to 115 mg
( Ex tr act W) . In or der to make th is mix tur e f r ee ? oWing,
aer ated s ilica 20 to 100 mg Was th or ough ly mix ed togeth er .
Th is mix tur e Was th en us ed to make eith er tablets , h ar d
gelatin caps ules or Veggie caps ules 200 to 900 mg each . Th is
uniq ue mix tur e h elps to balance body metabolis m to s uppor t
h ealth y ch oles ter ol lev els and to s uppor t car diov as cular
h ealth Wh en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 9
[ 0083] Compos ition containing potentiated poWder of
Sh atav ar i ( As par agus r acemas us ) f or s uppor ting Womens
h ealth .
[ 0084 ] Sh atav ar i ( As par agus r acemas us ) poWder 5 0 to
200 mg potentiated With Sh atav ar i r oot SCO2 ex tr act 1 to 15
mg ( Ex tr act C) , Sh atav ar i r oot pos t s uper cr itical h ydr oph ilic
US 2006/0193928 A1
ex tr act 265 to 4 60 mg ( Ex tr act W) , Hemides mus indicus r oot
SCO2 ex tr act 23 to 7 0 mg ( Ex tr act C) , Hemides mus indicus
pos t- s uper cr itical h ydr o ex tr act 7 5 to 17 0 mg ( Ex tr act W) ,
Ber ber ies ar is lala r oot SCO2 ex tr act 7 to 25 mg ( Ex tr act C) ,
Ber ber ies ar is lala pos t s uper cr itical h ydr o ex tr act 16 to 4 7
mg ( Ex tr act W) and Long pepper ( Piper longum) f r uit SCO2
ex tr act 1 to 10 mg ( Ex tr act C) . In or der to make th is mix tur e
f r ee ? ow ing, aer ated s ilica 15 to 100 mg w as th or ough ly
mix ed togeth er . Th is mix tur e w as th en us ed to make eith er
tablets , h ar d gelatin caps ules or Veggie caps ules 200 to 900
mg each . Th is mix tur e h elps to elev ate v itality, ener gy and
s pir it, s uppor ts nor mal dev elopment and h ealth of f emale
r epr oductiv e s ys tem, th is h er bs complex w ill h elp to s uppor t
pr egnancy and lactation w h en adminis ter ed or ally in des ir ed
dos ages .
EXAMPLE 10
[ 0085 ] Compos ition containing mix tur e of potentiated
Tur mer ic ( Cur cuma longa) & As h w agandh a ( Wilh ania s om
nif er a) s uppor ting cancer th er apy & impr ov ing q uality of
lif e f or cancer patients .
[ 0086] Tur mer ic pow der 30 to 200 mg and As h w agandh a
r oot pow der 30 to 200 mg potentiated w ith Tur mer ic r h i
Z ome SCO2 ex tr act 80 to 220 mg ( Ex tr act C) , As h w agandh a
r oot SCO2 ex tr act 1 to 20 mg ( Ex tr act C) , As h w agandh a
r oot pos t s uper cr itical h ydr o ex tr act 80 to 230 mg of ( Ex tr act
W) , Tinos por a car dif olia r oot SCO2 ex tr act 5 to 4 5 mg
( Ex tr act C) , ? nos por a car dif olia pos t s uper cr itical h ydr o
ph ilic ex tr act 5 0 to 260 mg ( Ex tr act W) , G inger ( Z ingiber
o? icinale) r h iZ omes SCO2 ex tr act 8 to 32 mgs ( Ex tr act C)
and N eem leaf ( Az adir ach la indica) SCO2 ex tr act 2 to 15
mgs ( Ex tr act C) . In or der to make th is mix tur e f r ee ? ow ing,
aer ated s ilica 7 0 to 190 mg w as th or ough ly mix ed togeth er .
Th is mix tur e w as th en us ed to make eith er tablets , h ar d
gelatin caps ules or Veggie caps ules 5 00 to 900 mgs each .
Th is uniq ue mix tur e h elps to s uppor t h ealth y and nor mal cell
gr ow th , pr ev ent naus ea and v omiting as s ociated w ith cancer
tr eatment. Tur mer ic and G inger ar e know n f or COX- 2
inh ibition w h en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 11
[ 0087 ] Compos ition containing potentiated As h w agandh a
( Wilh ania s omnlf er a) & Tinos por a car dlf olia pow der f or
tr eating Ar th r itis .
[ 0088] As h w agandh a ( Wilh ania s omnif er a) pow der 5 0 to
200 mg and Tinos por a car dif olia pow der 5 0 to 200 mg,
Bos w ellia ex tr act pow der 90 to 220 mgs , potentiated w ith
As h w agandh a ( Wilh ania s omnif er a) r oot SCO2 ex tr act 1 to
12 mg ( Ex tr act C) , As h w agandh a r oot pos t- s uper cr itical
h ydr o ex tr act 60 to 180 mg ( Ex tr act W) , Tinos por a car di
f olia r oot SCO2 ex tr act 10 to 38 mg ( Ex tr act C) , Tinos por a
car dif olia 110 to 260 mg pos t- s uper cr itical h ydr o ex tr act
( Ex tr act W) , Tr ibulus ter es tr is r oot SCO2 ex tr act 20 to 60
mg ( Ex tr act C) , Tr ibulus ter es tr is r oot 4 0 to 120 mg of
pos t- s uper cr itical h ydr oph ilic ex tr act ( Ex tr act W) , and G in
ger ( Z ingiber o? icinale) r h iz omes SCO2 ex tr act 3 to 22 mg
( Ex tr act C) . In or der to make th is mix tur e f r ee ? ow ing,
aer ated s ilica 20 to 100 mg w as th or ough ly mix ed togeth er .
Th is mix tur e w as th en us ed to make eith er tablets , h ar d
gelatin caps ules or Veggie caps ules 200 to 900 mg each . Th is
mix tur e h elps to r educe in? ammation, pr omotes h ealth y
j oints f unctions , us ed as mild analges ic containing h er bal
Aug. 31, 2006
anti- aging ph yto- nutr ients th at inactiv ate f r ee r adicals , pr o
motes nor mal cell th er eby impr ov ing th e q uality of lif e of
patients s uf f er ing f r om ar th r itis w h en adminis ter ed or ally in
des ir ed dos ages .
EXAMPLE 12
[ 0089] Compos ition containing is mix tur e of potentiated
Cor iander ( Cor iandr um s aliv um) pow der and Tur mer ic
( Cur cuma Iona) pow der to h elp aller gic patients .
[ 0090] Tur mer ic r h iZ ome pow der 90 to 225 mg and Cor i
ander s eed pow der 17 0 to 385 mg potentiated w ith Tur mer ic
r h iZ omes SCO2 ex tr act 4 0 to 115 mg ( Ex tr act C) , Cor iander
s eed SCO2 ex tr act 5 0 to 135 mg ( Ex tr act C) , N eem leaf
( Az adir ach la indica) SCO2 ex tr act 3 to 20 mg ( Ex tr act C)
and Black pepper ( Piper nigr um) f r uit SCO2 ex tr act 3 to 22
mg ( Ex tr act C) . In or der to make th is mix tur e f r ee ? ow ing,
aer ated s ilica 20 to 100 mg w as th or ough ly mix ed togeth er .
Th is mix tur e w as th en us ed to make eith er tablets , h ar d
gelatin caps ules or Veggie caps ules 200 to 900 mg each . Th is
compos ition h elps to impr ov e ener gy at cellular lev els ,
pr ev ent inf ections and act as anti- aller gy h er bs w h en admin
is ter ed or ally in des ir ed dos ages .
EXAMPLE 13
[ 0091] Compos ition containing potentiated def atted
Fenugr eek ( Tr igonella f oenum- gr aecum) pow der and Tur
mer ic ( Cur cuma longa) pow der f or s uppor ting patients
s uf f er ing f r om Type II diabetes
[ 0092] D ef atted Fenugr eek pow der 25 0 to 4 00 mg and
Tur mer ic pow der 5 0- 15 0 mg potentiated w ith Tur mer ic
r h iZ omes SCO2 ex tr act 5 0 to 120 mg ( Ex tr act C) , N eem leaf
( Az adir ach la Incia) SCO2 ex tr act 4 to 12 mg ( Ex tr act C) ,
Tinos por a car dif olia SCO2 ex tr act 10 to 30 mg ( Ex tr act C) ,
and Tinos por a car dif olia pos t s uper cr itical h ydr oph ilic
ex tr act 7 0 to 180 mg ( Ex tr act W) . In or der to make th is
mix tur e f r ee ? ow ing, aer ated s ilica 20 to 100 mg w as
th or ough ly mix ed togeth er . Th is mix tur e w as th en us ed to
make eith er tablets , h ar d gelatin caps ules or Veggie caps ules
200 to 900 mg each . Th is f or mulation h elps to r egulate th e
blood s ugar lev els , h ear t and liv er f unctions and neur o
f unctions , w h ich ar e under cons tant s tr es s in cas e of diabetic
patients , w h en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 14
[ 0093] Compos ition containing Tur mer ic ( Cur cuma
longa) and Tinos por a Car dif olia pow der s f or h eapto pr o
tection.
[ 0094 ] Tur mer ic pow der 5 0 to 100 mg and Tinos por a
car dif olia pow der 5 0 to 200 mg potentiated w ith Tinos por a
car dif olia SCO2 ex tr act 4 to 25 mg ( Ex tr act C) , Tinos por a
pos t s uper cr itical h ydr oph ilic ex tr act 5 0 to 15 0 mg ( Ex tr act
W) , Tur mer ic ( Cur cuma longa) SCO2 ex tr acts 25 to 7 5 mg
( Ex tr act C) , Eclipta alba SCO2 ex tr act 5 to 20 mg ( Ex tr act
C) , and Eclipta alba pos t s uper cr itical h ydr oph ilic ex tr act 4 0
to 100 mg ( Ex tr act W) . In or der to make th is mix tur e f r ee
? ow ing, aer ated s ilica 20 to 100 mg w as th or ough ly mix ed
togeth er . Th is mix tur e w as th en us ed to make eith er tablets ,
h ar d gelatin caps ules or Veggie caps ules 200 to 900 mg each .
Th is f or mulation h elps r educe dis comf or t to th os e s uf f er ing
f r om h epatitis conditions w h en adminis ter ed or ally in
des ir ed dos ages .
US 2006/0193928 A1
EXAMPLE 15
[ 0095 ] Compos ition containing potentiated Mucuna pr u
r iens & As h w agandh a ( w ilh ania s omnif er a) pow der f or
Men s h ealth .
[ 0096] As h w agandh a pow der 5 0 to 200 mg, Mucuna
pr ur iens pow der 5 0 to 200 mg and s af f r on pow der 3 to 10
mg potentiated w ith As h w agandh a r oot SCO2 ex tr act 5 to 20
mg ( Ex tr act C) , As h w agandh a Pos t s uper cr itical h ydr oph ilic
ex tr act 5 0 to 15 0 mg ( Ex tr act w ) , Tr ibulus Z er es lr is SCO2
ex tr act 10 to 5 0 mg ( Ex tr act C) , Tr ibulus Z er es lr is pos t
s uper cr itical ex tr act 25 to 7 5 mg ( Ex tr act W) , Mucuna
pr ur iens SCO2 ex tr act 10 to 4 0 mg, and Talimkh ana
( As ler ocanlh a longif olia) SCO2 ex tr act 5 to 20 mg ( Ex tr act
C) . In or der to make th is mix tur e f r ee ? ow ing, aer ated s ilica
20 to 100 mg w as th or ough ly mix ed togeth er . Th is mix tur e
w as th en us ed to make eith er tablets , h ar d gelatin caps ules
or Veggie caps ules 200 to 900 mg each . Th is h elps to
impr ov e libido, incr eas e s tr ength and s tamina and incr eas es
s per m count w h en adminis ter ed or ally in des ir ed dos ages .
EXAMPLE 16
[ 0097 ] Compos ition containing potentiated Ter minalia
ch ebula pow der f or Weigh t management.
[ 0098] Ter minalia ch ebula pow der 5 0 to 15 0 mg potenti
ated w ith Ter minalia ch ebula SCO2 ex tr act 4 to 20 mg
( Ex tr act C) , Ter minalia ch ebula pos t s uper cr itical h ydr o
ph ilic ex tr act 4 0 to 100 mg ( Ex tr act W) , Ter minalia beller ica
SCO2 ex tr act 2 to 10 mg ( Ex tr act C) , Ter minalia beller ica
pos t s uper cr itical h ydr oph ilic ex tr act 10 to 4 0 mg ( Ex tr act
W) , Vz ' j ' ays ar ( as na) SCO2 ex tr act 3 to 20 mg ( Ex tr act C) ,
Pler ocar pus Mar s upium pos t s uper cr itical h ydr oph ilic
ex tr act 25 to 7 5 mg ( Ex tr act W) , G inger ( Z ingiber o? icinale)
SCO2 ex tr act 1 to 8 mg ( Ex tr act C) , Black Pepper ( Piper
nigr um) SCO2 ex tr act 1 to 8 mg ( Ex tr act C) , Long pepper
( Piper longum) SCO2 ex tr act 1 to 8 mg ( Ex tr act C) , Embel
lica r ibes SCO2 ex tr act 2 to 20 mg ( Ex tr act C) , Cyper us
r olundus SCO2 ex tr act 2 to 20 mg ( Ex tr act C) , Plumbago
Z elanica SCO2 ex tr act 2 to 15 mg ( Ex tr act C) , Plumbago
Z elanica pos t s uper cr itical ex tr act 5 to 25 mg. ( Ex tr act W) .
In or der to make th is mix tur e f r ee ? ow ing, aer ated s ilica 20
to 100 mg w as th or ough ly mix ed togeth er . Th is mix tur e w as
th en us ed to make eith er tablets , h ar d gelatin caps ules or
Veggie caps ules 200 to 900 mg each . Th is h elps to r educe
abs or ption of f ats , enh ances f at metabolis m, impr ov es lipid
pr o? le and h elps to r educe body w eigh t w h en adminis ter ed
or ally in des ir ed dos ages .
Aug. 31, 2006
Hav ing, th us , des cr ibed th e inv ention w h at is claimed is :
1. A pr oces s f or ex tr acting bene? cial ex tr activ es f r om at
leas t one s elected th er apeutic h er b, compr is ing:
( a) cleaning th e at leas t one h er b;
( b) pow der ing th e at leas t one h er b;
( c) s ubj ecting th e at leas t one h er b to s uper cr itical CO2
ex tr action to obtain a ? r s t s olute and a ? r s t pow der
r es idue, th e ? r s t s olute de? ning a ? r s t ex tr act;
( d) s ubj ecting th e ? r s t r es idue to ex tr action w ith a mix tur e
of s uper cr itical CO2 and an alkanol to obtain a s econd
s olute and a s econd r es idue;
( e) r emov ing th e alkanol f r om th e s econd s olute to f or m
a s econd ex tr act, and
( f ) s ubj ecting th e s econd r es idue to w ater ex tr action to
obtain w ater s oluble ex tr activ es , th e ex tr activ es de? n
ing a th ir d ex tr act.
2. Th e pr oces s of claim 1 w h er ein th e th ir d ex tr act is dr ied
af ter ex tr action to f or m a f r ee ? ow ing pow der .
3. Th e pr oces s of claim 1 w h ich f ur th er compr is es mix ing
togeth er th e ? r s t ex tr act and th e s econd ex tr act to f or m a
f our th ex tr act.
4 . Th e pr oces s of claim 1 w h er ein th e ? r s t s uper cr itical
ex tr action ex tr acts all temper atur e s ens itiv e lypoph ilic com
ponents of th e h er b.
5 . Th e pr oces s of claim 1 w h ich f ur th er compr is es mix ing
togeth er th e th ir d and f our th ex tr acts to f or m a ? f th ex tr act.
6. Th e pr oces s of claim 3 w h ich f ur th er compr is es :
mix ing togeth er th e th ir d and f our th ex tr acts , th e pr oces s
f ur th er compr is ing mix ing th er ew ith aer ated s ilica to
f or m a f r ee ? ow ing pow der .
7 . Th e pr oces s of pr ev ious claim 6 w h ich f ur th er com
pr is es mix ing togeth er th e ? r s t ex tr act, th e s econd ex tr act
and th e f our th ex tr act to f or m a unif or m matr ix .
8. Th e pr oces s of claim 1 w h er ein th e h er b is dr ied in a
s h ed.
9. A meth od f or potentiating a th er apeutic pow der of at
leas t one h er b w h ich compr is es :
admix ing w ith th e th er apeutic pow der a ? r s t, a s econd and
a f our th ex tr act,
encaps ulating th e admix tur e in a v egetar ian caps ule, and
w h er ein th e ex tr acts ar e obtained by th e pr oces s of claim
3.
10. Th e meth od of claim 9 w h er ein th e th er apeutic
pow der is a r aw h er b pow der .
* * * * *